NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) is navigating a complex landscape of record-breaking financial performance and renewed legal challenges as of March 01 2026. While the healthcare giant’s stock reached a new 52-week high of $248.94 this week, the company faces a fresh wave of litigation involving its talc-based products and a high-profile false advertising lawsuit from competitor Bayer.
Market Performance and Institutional Shifts
Despite ongoing legal headwinds, JNJ shares demonstrated significant strength in late February 2026. The stock climbed 2.2% on Friday, closing near its annual peak. This surge comes as investors weigh the company’s diversified healthcare portfolio against recent jury verdicts. However, several institutional investors have adjusted their positions; Tounjian Advisory Partners LLC and Close Asset Management Ltd reduced their stakes by 36.8% and 30.0% respectively, while Generali Investments Management Co LLC increased its holdings by over 71%.
New Legal Challenges: Talc Verdicts and Bayer Lawsuit
The company’s legal department remains active as a Philadelphia jury recently found Johnson & Johnson liable in a talc-related ovarian cancer lawsuit. The verdict, which ordered the company to pay $250,000 in damages, marks the first plaintiff victory in Philadelphia since litigation in that jurisdiction restarted. This follows years of controversy surrounding the safety of its legacy baby powder products.
Simultaneously, Bayer has filed a lawsuit against J&J’s Janssen Biotech unit. The suit accuses Johnson & Johnson of false advertising regarding its prostate cancer drug, Erleada. Bayer alleges that J&J’s promotional claims—which suggest Erleada reduces the risk of death more effectively than Bayer’s rival drug, Nubeqa—are “deeply flawed” and do not meet FDA standards for substantial evidence.
Strategic Growth and Innovation
Amidst the courtroom battles, Johnson & Johnson continues to expand its footprint in oncology and medical technology. Key updates include:
- Pennsylvania Expansion: The company announced a major investment in Pennsylvania facilities to bolster its cancer research and manufacturing capabilities.
- Robotics Divestiture: Quantum Surgical recently acquired J&J’s NeuWave cancer robotics business, a move that aligns with J&J’s strategy to streamline its MedTech portfolio toward high-margin digital surgery solutions.
- Pharmaceutical Strength: Top revenue-producing drugs such as Stelara, Darzalex, and Tremfya continue to drive the company’s $45.6 billion pharmaceutical segment.
A Legacy of Healthcare Leadership
Founded in 1886, Johnson & Johnson has evolved from a pioneer in antiseptic surgical supplies into a global healthcare powerhouse. With a history spanning over 135 years, the company remains a staple of the Dow Jones Industrial Average, valued for its consistent dividend growth and its ability to maintain stability during market volatility. As of March 2026, the company’s market capitalization stands at approximately $598.3 billion, reflecting its enduring role as a cornerstone of the global pharmaceutical industry.